SCHEMBL1706523

SCHEMBL1706523

CC(=O)c1coc(CC(=O)O)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAGLA Q9Y4D2 1/20 0.40
FPR2 P25090 4/20 0.38
NR4A1 P22736 1/20 0.36
NR4A2 P43354 1/20 0.36
NR4A3 Q92570 1/20 0.36
POLB P06746 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ALOX15 P16050 2/20 0.33
FPR3 P25089 1/20 0.33
HRH3 Q9Y5N1 2/20 0.33
GAA P10253 1/20 0.33
HDAC6 Q9UBN7 1/20 0.32
KDM4E B2RXH2 2/20 0.32
MAPT P10636 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
ABL1 P00519 1/20 0.32
RECQL P46063 1/20 0.32
RIN1 Q13671 1/20 0.32
CTDSP1 Q9GZU7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19871354 0.81 FPR2 (0.40) DAGLAFPR2FPR3HRH3GAA
SCHEMBL1166830 0.81 FPR2 (0.42) DAGLAFPR2FPR3HRH3HDAC6
SCHEMBL16213693 0.79 FPR2 (0.39) DAGLAFPR2FPR3HRH3HDAC6
SCHEMBL9926019 0.79 FPR2 (0.39) DAGLAFPR2FPR3HRH3HDAC6
SCHEMBL13820314 0.79 FPR2 (0.39) DAGLAFPR2KMT2AFPR3HRH3
SCHEMBL12380047 0.77 ALOX15 (0.39) NR4A1NR4A2NR4A3KMT2AALOX15
SCHEMBL14076074 0.76 FPR2 (0.45) DAGLAFPR2FPR3HRH3HDAC6
SCHEMBL21333174 0.76 DAGLA (0.52) DAGLAFPR2MEN1KMT2AMAPT
Benzene SCHEMBL6105537 0.76 NR4A2 (0.40) NR4A1NR4A2NR4A3ALOX15GAA
SCHEMBL12410005 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102803237-B Oxazole and thiazole derivatives as alx receptor agonists ACTELION PHARMACEUTICALS LTD 2014-09-24 CN disclosed
US-8674111-B2 Oxazole and thiazole derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD. (CH) 2014-03-18 US disclosed
EP-2440536-B1 Oxazole and thiazole derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD (CH) 2013-11-06 EP disclosed
CN-102803237-A Oxazole and thiazole derivatives as alx receptor agonists ACTELION PHARMACEUTICALS LTD 2012-11-28 CN disclosed
US-20120115916-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2012-05-10 US disclosed
EP-2440536-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2012-04-18 EP disclosed
WO-2010143158-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115916-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS P2RX1, GLP1R, P2RX7 DAGLA 3893/4885FPR2 156/4885NR4A1 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.